Itaconix plc

Itaconix reported H1 2026 total revenue of $8.3 million, up 72% half over half. Itaconix Performance Ingredients revenue more than doubled to $6.7 million. Gross profit was $3 million, up 74%, and gross margin remained stable at 36%. The company said it reached adjusted EBITDA breakeven, versus a $200,000 loss in H1 2025. North American revenue rose about 29% half over half, while EMEA revenue grew 166%. At period end, cash and investments were $5.1 million, versus $4.4 million at the end of 2025, and working capital was about $4.4 million. For the second half of 2026, management said it needs to exceed $14.8 million in revenue and deliver clear EBITDA profitability; for the medium term, it reiterated a $30 million revenue ambition in three to four years and said it can reach that with existing U.S. operations.

John Shaw framed the first half as a milestone period, emphasizing record revenue, commercial momentum, and the company’s first half of break-even EBITDA profitability. He said the business is being built around existing customer expansion, new customer wins, and investments in new products, applications, and production capabilities. Shaw was notably upbeat about the long-term opportunity, saying Itaconix is not aiming to be just a $30 million company and sees a path to at least $100 million over time through detergents, paints, and crops.

Laura Denner highlighted the core financial progression: $8.3 million revenue, $3 million gross profit, 36% gross margin, and adjusted EBITDA breakeven. She said gross profit rose by about $1.2 million while administrative expenses increased by about $1 million to about $3.2 million, reflecting personnel, product development, transportation, and commercial spending tied to growth. She also noted the balance sheet remained strong with $5.1 million of cash and investments, working capital of about $4.4 million, and only modest additional working-capital needs of about $300,000-$400,000. She said the current infrastructure appears sufficient for the $30 million target and that most plant improvements have been achieved without significant capex.

The most notable Q&A focused on what it would take to sustain profitability and support future growth. Management said they largely already have the capacity and people needed for the $30 million target, but would need one more major EMEA customer win and more traction in North American unit-dose detergency. On supply chain and margins, they acknowledged exposure to China because itaconic acid is only produced there, but said they are comfortable with supplier relationships and are using selective price increases and surcharges to manage tariffs and shipping-cost changes. They also made clear they are not seeking an acquisition or strategic combination now, and they do not plan to dilute equity to fund a future additional production operation.